Sierra Oncology

June 05, 2019

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.

Does amount matter when it comes to a biotech IPO?

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Lilly scraps two research assets, leaving few rivals behind

Where is the IPO class of 2014-15 now?

Select small caps stand out amid wider 2016 stock market declines

Patience rewards Ionis and Ziarco

Returns hint at gradual decline in quality of biotech floats

Lively M&A scene keeps biotech shares buoyant in Q3

Genmab and Tesaro lead first-half gainers as Endo and Infinity falter

Bristol-Myers buys back Medarex discard

Asco event analyser – 2016’s winners and losers

Latest Reports

Biopharma Quarterly Round Up (Q3 2021)

Covid Round Up (2021)

Editor's Picks

The bubble bursts for biotech stocks

Ash 2021 preview – as competition grows Autolus monetises

Ash 2021 late-breakers enable neat comparisons

What Novartis could buy with its windfall

Fate buries bad data and moves on